JPMorgan says a “close win is still a win” after an FDA panel voted 8-6 in favor of Sarepta Therapeutics’ SRP-9001. The the positively skewed vote helps de-risk the ultimate accelerated approval of SRP-9001, the analyst tells investors in a research note. The firm sees the shares having the potential to “grind to” the $150-$175 with time and go higher on a potential approval. Friday’s vote is a “big win” for Sarepta, says JPMorgan. The firm reiterates an Overweight rating on the shares with a $206 price target.
previous post